Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rapport Therapeutics, Inc. - Common Stock (NQ: RAPP )

13.67 -0.37 (-2.64%)
Streaming Delayed Price Updated: 3:45 PM EST, Feb 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 68,034
Open 13.78
Bid (Size) 13.66 (7)
Ask (Size) 13.74 (1)
Prev. Close 14.04
Today's Range 13.16 - 14.60
52wk Range 12.09 - 29.74
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders
From Rapport Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-25.67%
-25.67%
1 Month
+3.01%
+3.01%
3 Month
-38.64%
-38.64%
6 Month
-37.86%
-37.86%
1 Year
-34.28%
-34.28%

More News

Read More
Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Rapport Therapeutics Reports Third Quarter Financials and Provides Business Update
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November
From Rapport Therapeutics, Inc.
Via GlobeNewswire
This Rapport Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Via Benzinga
Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen’s 4th Annual Novel Mechanisms in Neuropsychiatry Summit
From Rapport Therapeutics, Inc.
Via GlobeNewswire
The 3 Best Healthcare Stocks to Buy in August 2024
Via InvestorPlace
RAPP Stock Earnings: Rapport Therapeutics Misses EPS for Q2 2024
Via InvestorPlace
Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update
From Rapport Therapeutics, Inc.
Via GlobeNewswire
3 Under-The-Radar Healthcare Stocks to Buy for Outsized Returns
Via InvestorPlace
Rapport Therapeutics to Present Data for TARPγ8 AMPAR Negative Modulator at IASP 2024 World Congress on Pain
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
From Rapport Therapeutics, Inc.
Via GlobeNewswire
Why Contango Ore Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.